Procarbazine

"Procarbazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

Descriptor ID	D011344
MeSH Number(s)	D02.065.277.727 D02.241.223.100.100.655 D02.455.426.559.389.127.085.655
Concept/Terms	Procarbazine Procarbazine Procarbazine Monohydrobromide Procarbazine Monohydrobromide Monohydrobromide, Procarbazine Procarbazine Hydrochloride Procarbazine Hydrochloride Hydrochloride, Procarbazine Procarbazine Monohydrochloride Monohydrochloride, Procarbazine Matulane Matulane Natulan Natulan

Below are MeSH descriptors whose meaning is more general than "Procarbazine".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Benzamides [D02.065.277]
Procarbazine [D02.065.277.727]
Carboxylic Acids [D02.241]
Acids, Carbocyclic [D02.241.223]
Benzoates [D02.241.223.100]
Benzamides [D02.241.223.100.100]
Procarbazine [D02.241.223.100.100.655]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Benzoates [D02.455.426.559.389.127]
Benzamides [D02.455.426.559.389.127.085]
Procarbazine [D02.455.426.559.389.127.085.655]

Below are MeSH descriptors whose meaning is related to "Procarbazine".

Below are MeSH descriptors whose meaning is more specific than "Procarbazine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Procarbazine" by people in this website by year, and whether "Procarbazine" was a major or minor topic of these publications.

Bar chart showing 4 publications over 4 distinct years, with a maximum of 1 publications in 1996 and 1997 and 2002 and 2004

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
1996	1	1
1997	1	1
2002	1	1
2004	1	1

Below are the most recent publications written about "Procarbazine" by people in Profiles.

Pandya KJ, Lefkopoulou M, Petrelli NJ, Vaughn DJ, Smith TJ, Harris JE, Haller DG. Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285). Oncology. 2004; 66(2):118-25.

View in: PubMed
Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002 Jul 15; 20(14):3081-7.

View in: PubMed
Golden MA, Vaughn DJ, Crooks GW, Holland GA, Bavaria JE. Aortic dissection in a patient receiving chemotherapy for Hodgkin's disease--a case report. Angiology. 1997 Dec; 48(12):1063-5.

View in: PubMed
Shchepotin IB, Evans SR, Shabahang M, Chorny V, Buras RR, Korobko V, Zadorozhny A, Nauta RJ. Primary non-Hodgkin's lymphoma of the stomach: three radical modalities of treatment in 75 patients. Ann Surg Oncol. 1996 May; 3(3):277-84.

View in: PubMed
Vinciguerra V, Propert KJ, Coleman M, Anderson JR, Stutzman L, Pajak TF, Nissen NI, Frizzera G, Gottlieb A, Holland JF. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol. 1986 Jun; 4(6):838-46.

View in: PubMed
Lanzillo JH, Moylan DJ, Mohiuddin M, Kramer S. Radiotherapy of stage I and II Hodgkin disease with inguinal presentation. Radiology. 1985 Jan; 154(1):213-5.

View in: PubMed
Tester WJ, Kinsella TJ, Waller B, Makuch RW, Kelley PA, Glatstein E, DeVita VT. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol. 1984 Jul; 2(7):762-9.

View in: PubMed
Cooper MR, Pajak TF, Gottlieb AJ, Glicksman AS, Nissen N, Richards F, Bloomfield C, Holland JF. The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease. J Clin Oncol. 1984 Jul; 2(7):748-55.

View in: PubMed
Bloomfield CD, Pajak TF, Glicksman AS, Gottlieb AJ, Coleman M, Nissen NI, Rafla S, Stutzman L, Vinciguerra V, Glidewell OJ, Holland JF. Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep. 1982 Apr; 66(4):835-46.

View in: PubMed
Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15; 46(4):654-62.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement